United States Patent 9,102,731 (US9102731): Claim Analysis and US Patent Landscape
Executive summary
US Patent 9,102,731 is a US patent with enforceable, claim-defined subject matter and a defined prosecution and maintenance history that determines practical freedom-to-operate (FTO) outcomes in the US. A complete, claim-by-claim validity and landscape analysis cannot be produced from the information provided. The prompt does not include the patent’s claim text (“The claims are: …”), nor any claim set metadata (independent claims, dependent claims, numbering, dates, assignee, or asserted embodiments). Without the actual claim wording, no accurate mapping to claim scope, design-arounds, prior art touchpoints, or litigation/Orange Book relevance can be completed.
What does US Patent 9,102,731 claim, and what is its scope in plain English?
Cannot be analyzed from the provided input. Claim scope depends on the exact language of each independent and dependent claim, including limitations, ranges, structural features, and functional steps.
Which limitations typically drive claim breadth for US9102731?
Cannot be determined. The breadth and enforceability hinge on the specific claim elements.
How do dependent claims narrow the invention in US9102731?
Cannot be determined. Dependent claim structure is required to identify narrower fallbacks and the likely “center of gravity” of enforceable coverage.
How strong is the patent estate around US9102731 in the US?
A strength assessment requires two elements that are not present: (1) the actual claim subject matter and (2) a search corpus anchored to that subject matter. The provided input does not allow a lawful, accurate determination of nearby US filings, family members, continuation activity, or cite relationships.
What related patents commonly share priority with US9102731?
Cannot be determined.
How many US family members and continuation patents exist for US9102731?
Cannot be determined.
Which assignees hold overlapping coverage with US9102731?
Cannot be determined.
When does US9102731 expire, and when can generic or biosimilar competitors enter?
Exclusivity and patent expiration depend on the filing date and any PTA/adjustments, continuation history, and term changes. Those facts are not provided. Patent term and possible earlier expiration due to terminal disclaimers also require file history data.
What is the expected expiration date of US9102731 under US term rules?
Cannot be determined.
Does US9102731 have patent term adjustment (PTA) or terminal disclaimers?
Cannot be determined.
Could any exclusivity block entry even after US9102731 expires?
Cannot be determined because the drug/active ingredient and FDA approval context are not provided.
What patents can compete with or design around US9102731?
Design-around risk is determined by how competitors would avoid each claim limitation. Without claim text, FTO mapping is not possible.
What claim elements are easiest to design around?
Cannot be determined.
What manufacturing or formulation changes can avoid infringement?
Cannot be determined.
How do the claims of US9102731 compare with nearby patents by other companies?
A meaningful comparison needs (1) claim language and (2) the relevant competitor patents in the same technical space. Neither is provided.
Which companies would likely face infringement risk from US9102731?
Cannot be determined.
Are there close alternatives with different structural or method-of-use limitations?
Cannot be determined.
What is the litigation and enforcement history for US9102731?
Litigation needs docket-level sources and claim/assertion mapping. No parties, forum, or complaint identifiers are provided.
Has US9102731 been asserted in district court?
Cannot be determined.
Have any settlements or consent judgments affected enforcement of US9102731?
Cannot be determined.
What is the US regulatory relevance of US9102731 (Orange Book, exclusivity, and Paragraph IV)?
Orange Book relevance is only assessable if the patent is listed for a specific FDA-approved product and if the patent type matches Orange Book categories. No drug product linkage or Orange Book listing data is provided.
What is the Orange Book status of US9102731?
Cannot be determined.
Is US9102731 a drug substance, drug product, or method-of-use listing?
Cannot be determined.
Would Paragraph IV challenges be directed to US9102731?
Cannot be determined.
What validations, prior art, and obviousness arguments could challenge US9102731?
Validity analysis depends on the specific claim limitations and the prior art that discloses them. The prompt provides none of the claim text or a claim-to-art mapping.
What prior art would most likely impact novelty (35 USC 102) for US9102731?
Cannot be determined.
What obviousness (35 USC 103) combinations are most plausible against the claim set?
Cannot be determined.
How would claim construction likely affect validity for US9102731?
Cannot be determined.
How do US9102731’s claim limitations map to likely prior art in the field?
This is a claim-by-claim exercise that requires the claim language. Without the claims, no mapping can be produced.
Are there critical terms that control infringement and validity?
Cannot be determined.
What claim interpretation issues usually arise for functional or result-based language?
Cannot be determined.
How does claim scope affect freedom-to-operate (FTO) in the US?
FTO is decided by each limitation’s presence or absence in the accused product or process. No accused product/process is provided, and the patent claims are missing.
What would be required to clear FTO for US9102731?
Cannot be determined.
What are the most likely infringement theories (literal infringement vs doctrine of equivalents)?
Cannot be determined.
Key Takeaways
- A comprehensive claim-level and landscape analysis of US Patent 9,102,731 cannot be completed without the patent’s claim text and claim set structure.
- Expiration, Orange Book status, Paragraph IV risk, and litigation relevance also require drug-product linkage and file-history data not provided.
- Once the claim language is supplied, the analysis should cover claim-by-claim scope, novelty and obviousness vulnerability, competitor design-arounds, expiration timeline, Orange Book listing category, and litigation enforcement posture.
FAQs
- What information is needed to perform a claim-by-claim infringement analysis for US9102731?
- How do PTA and terminal disclaimers change the effective enforcement window for US9102731?
- What Orange Book listing type (drug substance, drug product, method of use) most often determines Paragraph IV exposure?
- How do continuation patents and claim amendments usually reshape the effective claim scope of a US patent like US9102731?
- What are the most common validity attack routes (102/103/112) that affect process or method claims in US patents?
References
No sources were cited because no claim text, assignee/product linkage, or bibliographic identifiers were provided to support accurate referencing.
